Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Med.

Sec. Gastroenterology

Volume 12 - 2025 | doi: 10.3389/fmed.2025.1624815

Comprehensive Pan-Cancer Analysis Reveals CGB5 Is a Potential Promising Predictive and Immunotherapeutic Biomarker

Provisionally accepted
Shuni  ChenShuni Chen1Shan  LinShan Lin1*Feng  LiFeng Li1Haibin  HeHaibin He1Yuanjie  ZhangYuanjie Zhang1Guiping  MaGuiping Ma1Weifeng  YuWeifeng Yu2
  • 1Shenzhen Hospital, Beijing University of Chinese Medicine, Shenzhen, China
  • 2Shenzhen Hospital of Integrated Traditional and Western Medicine, Shenzhen, China

The final, formatted version of the article will be published soon.

Background: Existing studies substantiate the notion that CGB5 plays a pivotal role in various cancers, including gastric and ovarian cancers, and is strongly associated with patient prognosis. However, to date, there have been no comprehensive reports investigating the role of CGB5 in pan-cancer analysis. Methods: In this study, an in-depth investigation of CGB5 in pan-cancer was conducted through multiple public databases, including TCGA, HPA, UALCAN, cBioPortal Platform, GSCA, Kaplan-Meier Plotter, TIMER, TISIDB, SangerBox Website, and Metascape database. The genomic, transcriptomic, epigenetic, immune microenvironmental, and clinical prognostic significance of CGB5 across various cancers was systematically analyzed. Furthermore, CGB5 expression in gastric cancer cells was experimentally detected, and the potential mechanisms underlying its impact on prognosis were elucidated. Results: This study shows that CGB5 exhibits diverse expression patterns in most tumors, including high, low, or no significant expression changes. Compared to normal tissues, CGB5 is significantly up-regulated in six tumor types, such as liver, lung, and gastric cancers. Its expression correlates positively with tumor stroma content and immune grading but negatively with immunological markers. Additionally, CGB5 is associated with specific immune sub-types in various cancers, including endometrial, testicular germ cell, and gastric adenocarcinoma, and closely linked to clinical features of gastric cancer patients. CGB5 primarily involves immune-related pathways, such as "Primary immunodeficiency," "CD8 TCR signaling pathway," and "PD-1 checkpoint signaling". Conclusion: This study demonstrates that CGB5 expression is closely associated with immune cell infiltration across cancer types, showing significant variation in infiltration patterns among tumor types. CGB5 is significantly up-regulated in various malignancies and strongly correlates with cancer patient prognoses, specifically in malignancies like GC and PAAD. Overall, these findings indicate CGB5 as a promising biomarker for pan-cancer diagnosis and prognosis.

Keywords: Pan-cancer, gastric cancer, prognosis, oncogene, biomarker

Received: 08 May 2025; Accepted: 27 Aug 2025.

Copyright: © 2025 Chen, Lin, Li, He, Zhang, Ma and Yu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Shan Lin, Shenzhen Hospital, Beijing University of Chinese Medicine, Shenzhen, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.